Business Wire

MA-EXAGRID

30.6.2022 14:02:08 CEST | Business Wire | Press release

Share
ExaGrid Named to First-Ever MES Matters – Key Vendors Serving the Midmarket List

ExaGrid ®, the industry’s only Tiered Backup Storage solution, today announced that Midsize Enterprise Services (MES), a brand of The Channel Company , has recognized ExaGrid on its 2022 MES Matters- Key Vendors Serving the Midmarket list.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220630005185/en/

The MES Matters list recognizes vendors that have proven themselves to be forward-thinking technology providers offering solutions that support the growth and innovation of midmarket organizations.

MES defines the midmarket as an organization with an annual revenue of $50M-$2B and/or 100-2500 total supported users/seats. Companies were selected due to their go-to-market strategy, how they serve the midmarket, and the strength of their midmarket product portfolios.

ExaGrid focuses on the Midmarket to the Large Enterprise and offers the most value to customers who back up 50TB to 100s of PB of data, and keep data for long-term retention. Midmarket organizations in particular have a complex set of requirements for backup storage that include: working across a wide range of operating systems, network topologies and distributed environments, stringent security requirements, and managing massive data growth. In addition, Midmarket organizations have tight IT resources and budget dollars.

ExaGrid Tiered Backup Storage appliances were architected to work with all major backup applications and in any environment but with the easiest installation, easiest management, and the lowest cost up front and over time. Midmarket organizations need a solution that brings the appropriate compute with capacity to handle large data loads and massive data growth, with the least management possible. ExaGrid’s full appliances in a single system bring a scale-out architecture to backup storage at a price that is affordable. In addition, ExaGrid’s tiered storage architecture includes a non-network-facing repository (providing a virtual air gap) where data is stored as immutable objects, and enables a delayed delete policy with its Retention Time-Lock for Ransomware Recovery feature, and this functionality is an important consideration for Midmarket organizations in the wake of increasing ransomware and malware attacks.

“ExaGrid’s Tiered Backup Storage offers the key items that Midmarket organizations need for their backup infrastructure: A scale-out architecture that allows them to add appliances to their system as their data grows, so they only pay for what they need, with no costly forklift upgrades, as well as a backup storage solution that is ready for ransomware recovery,” said Bill Andrews, President and CEO. “We are honored to be recognized among the leading vendors that serve Midmarket organizations and look forward to providing more organizations with a backup storage solution that offers the best performance for the best value, up front and over time.”

“The MES Matters list is designed to recognize key vendors that are invested in the growth and development of midmarket organizations which according to Harvard Business Review 3/21, represent only 3% of US businesses but are responsible for 33% of private sector GDP and employment. Technology is often designed and priced for either the consumer in mind, or the extreme opposite for the heavy enterprise in mind. Midmarket organizations are unique in the way they are structured and as a result their technology needs and requirements from features to pricing are very different than other market segments” said Adam Dennison, VP Midsize Enterprise Services, The Channel Company. “The vendors and executives identified on this first-ever MES Matters list have shown a consistent commitment to help midmarket organizations succeed and thrive, they should be recognized and commended for their dedication to this important market segment”.

The MES Matters list is featured online at https://www.crn.com/rankings-and-lists/mes2022.htm

About ExaGrid

ExaGrid provides Tiered Backup Storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. ExaGrid offers the only two-tiered backup storage approach with a non-network-facing tier, delayed deletes, and immutable objects to recover from ransomware attacks.

ExaGrid has physical sales and pre-sales systems engineers in the following countries: Argentina, Australia, Benelux, Brazil, Canada, Chile, CIS, Colombia, Czech Republic, France, Germany, Hong Kong, Iberia, Israel, Japan, Mexico, Nordics, Poland, Saudi Arabia, Singapore, South Africa, South Korea, Turkey, United Arab Emirates, United Kingdom, United States, and other regions.

Visit us at exagrid.com or connect with us on LinkedIn . See what our customers have to say about their own ExaGrid experiences and learn why they now spend significantly less time on backup in our customer success stories .

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

About The Channel Company

The Channel Company enables breakthrough IT channel performance with our dominant media, engaging events, expert consulting and education, and innovative marketing services and platforms. As the channel catalyst, we connect and empower technology suppliers, solution providers, and end users. Backed by more than 30 years of unequalled channel experience, we draw from our deep knowledge to envision innovative new solutions for ever-evolving challenges in the technology marketplace. www.thechannelcompany.com

Follow The Channel Company : Twitter , LinkedIn , and Facebook .

© 2022 The Channel Company, LLC. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

Link:

ClickThru

Social Media:

https://www.facebook.com/ExaGrid/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye